Companies across the globe are working towards the development of novel treatment therapies for Hemophilia B. Additionally, some of the major pharma and biotech giants have also recently shifted their focus toward this indication.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia B market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Hemophilia B market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hemophilia B: An Overview
According to the Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleeding like haemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with Hemophilia B do not bleed faster than unaffected individuals; they bleed longer.
Hemophilia B Market Key Facts
In 2020, the overall prevalent cases of Hemophilia B were accessed to be around 10,700+ in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
In the United States, the total number of prevalent cases of Hemophilia B was 4,100+ in the year 2020.
In the year 2020, the total prevalent cases of Hemophilia B were 5,400+ in EU-5 countries.
Moderate and severe account for ~75% of the Hemophilia B patient pool. In the 7MM, there were around 8,054 moderate and severe Hemophilia B cases in 2020.
As per the Centre for Disease Control and Prevention, Hemophilia occurs in about 1 of every 5,000 male births, and Hemophilia A is about four times as common as Hemophilia B, and about half of those affected have a severe form.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hemophilia B market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Hemophilia B market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hemophilia B Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Hemophilia B Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers the Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Hemophilia B Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/hemophilia-b-market
Some of the key companies in the Hemophilia B Therapeutics Market include:
UniQure Biopharma B.V./ CSL Behring
Genzyme, a Sanofi Company/ Alnylam Pharmaceuticals
And many others
Hemophilia B Therapies Covered in the Report include:
Fitusiran: Sanofi/Alnylam Pharmaceuticals
Etranacogene dezaparvovec (AMT-061): CSL Behring/uniQure
Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
AMT-060 (AAV5-hFIX): UniQure
Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hemophilia B Competitive Intelligence Analysis
4. Hemophilia B Market Overview at a Glance
5. Hemophilia B Disease Background and Overview
6. Hemophilia B Patient Journey
7. Hemophilia B Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Hemophilia B Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia B Unmet Needs
10. Key Endpoints of Hemophilia B Treatment
11. Hemophilia B Marketed Products
12. Hemophilia B Emerging Drugs and Latest Therapeutic Advances
13. Hemophilia B Seven Major Market Analysis
14. Attribute Analysis
15. Hemophilia B Market Outlook (In US, EU5, and Japan)
16. Hemophilia B Access and Reimbursement Overview
17. KOL Views on the Hemophilia B Market
18. Hemophilia B Market Drivers
19. Hemophilia B Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
“Hemophilia B Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B market.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States